A new trading day began on Friday, with CytomX Therapeutics Inc (NASDAQ: CTMX) stock price down -16.11% from the previous day of trading, before settling in for the closing price of $0.54. CTMX’s price has ranged from $0.54 to $5.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 36.21% over the past five years. Meanwhile, its annual earnings per share averaged -97.15%. With a float of $78.13 million, this company’s outstanding shares have now reached $80.10 million.
Let’s look at the performance matrix of the company that is accounted for 121 employees. In terms of profitability, gross margin is 99.33%, operating margin of 18.1%, and the pretax margin is 23.24%.
CytomX Therapeutics Inc (CTMX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc is 2.46%, while institutional ownership is 58.45%. The most recent insider transaction that took place on Mar 18 ’25, was worth 22,556. In this transaction CEO of this company sold 37,656 shares at a rate of $0.60, taking the stock ownership to the 995,195 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Financial Officer sold 8,551 for $0.60, making the entire transaction worth $5,122. This insider now owns 201,026 shares in total.
CytomX Therapeutics Inc (CTMX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -97.15% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Here are CytomX Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.39, a number that is poised to hit 0.06 in the next quarter and is forecasted to reach -0.48 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc (NASDAQ: CTMX) saw its 5-day average volume 1.32 million, a negative change from its year-to-date volume of 1.8 million. As of the previous 9 days, the stock’s Stochastic %D was 14.10%. Additionally, its Average True Range was 0.06.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 0.53%, which indicates a significant decrease from 2.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 111.51% in the past 14 days, which was higher than the 82.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7130, while its 200-day Moving Average is $1.0447. Nevertheless, the first resistance level for the watch stands at $0.5222 in the near term. At $0.5887, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.6246. If the price goes on to break the first support level at $0.4198, it is likely to go to the next support level at $0.3839. The third support level lies at $0.3174 if the price breaches the second support level.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
With a market capitalization of 36.49 million, the company has a total of 80,100K Shares Outstanding. Currently, annual sales are 138,100 K while annual income is 31,870 K. The company’s previous quarter sales were 38,090 K while its latest quarter income was 18,880 K.
